PMC:7276974 / 2488-2674 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T44","span":{"begin":96,"end":106},"obj":"SP_7"},{"id":"T45","span":{"begin":107,"end":113},"obj":"UBERON:0001969"},{"id":"T46","span":{"begin":179,"end":185},"obj":"UBERON:0001969"}],"text":"Study participants will be randomized in a 2:1 ratio to receive one unit (200 – 250 mL) of anti-SARS-CoV-2 plasma versus one unit (200 – 250 mL) of the earliest available control plasma."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T15","span":{"begin":107,"end":113},"obj":"Body_part"},{"id":"T16","span":{"begin":179,"end":185},"obj":"Body_part"}],"attributes":[{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"Study participants will be randomized in a 2:1 ratio to receive one unit (200 – 250 mL) of anti-SARS-CoV-2 plasma versus one unit (200 – 250 mL) of the earliest available control plasma."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T23","span":{"begin":96,"end":104},"obj":"Disease"}],"attributes":[{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Study participants will be randomized in a 2:1 ratio to receive one unit (200 – 250 mL) of anti-SARS-CoV-2 plasma versus one unit (200 – 250 mL) of the earliest available control plasma."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T32","span":{"begin":41,"end":46},"obj":"http://purl.obolibrary.org/obo/CLO_0053711"},{"id":"T33","span":{"begin":107,"end":113},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T34","span":{"begin":179,"end":185},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"Study participants will be randomized in a 2:1 ratio to receive one unit (200 – 250 mL) of anti-SARS-CoV-2 plasma versus one unit (200 – 250 mL) of the earliest available control plasma."}

{"project":"LitCovid-sentences","denotations":[{"id":"T19","span":{"begin":0,"end":186},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Study participants will be randomized in a 2:1 ratio to receive one unit (200 – 250 mL) of anti-SARS-CoV-2 plasma versus one unit (200 – 250 mL) of the earliest available control plasma."}

{"project":"LitCovid-PubTator","denotations":[{"id":"62","span":{"begin":6,"end":18},"obj":"Species"},{"id":"65","span":{"begin":96,"end":106},"obj":"Species"}],"attributes":[{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"Tax:9606"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Study participants will be randomized in a 2:1 ratio to receive one unit (200 – 250 mL) of anti-SARS-CoV-2 plasma versus one unit (200 – 250 mL) of the earliest available control plasma."}